Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN ‐1 Trial
Primary result · Mean relative reduction from baseline in T2D risk score (Cardiometabolic Disease Staging)Result — go to the resultHR-range 0.43-0.55Authors' conclusion
In this post hoc analysis, once-daily oral orforglipron was associated with statistically significant improvements in predicted 10-year risk of incident T2D and CVD compared with placebo over 72 weeks using three validated risk prediction models.
Study context
- Population
- Adults (≥18 years) with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m² with ≥1 obesity-related complication) without T2D
- Comparison
- Orforglipron 5.5 mg, 9 mg or 17.2 mg vs placebo
- Primary endpoint
- Change in predicted 10-year T2D risk (Cardiometabolic Disease Staging) and CVD risk (Framingham; PREVENT: total CVD, ASCVD, HF)
- Follow-up
- Baseline to 72 weeks
Methodological detailspost hoc analysis, phase 3, placebo-controlled
- Post hoc analysis
- Phase 3
- Placebo-controlled
Primary result
As reported in the abstract
Mean relative reduction from baseline in T2D risk score (Cardiometabolic Disease Staging) · week 72
HR-range
0.43-0.55
P < 0.0001
- Mean relative reduction, orforglipron doses (range)
- −48.6% to −59.4%
- Mean relative reduction, placebo
- −10.5%
- Median baseline scores
- 16.0%-17.3%
Further findings
| Outcome | Placebo | HR range | P value |
|---|---|---|---|
| Mean absolute change in total CVD risk (Framingham) · week 72Orforglipron vs Placebo | mean +0.6% | 0.82-0.87 | P < 0.0001 |
- Mean absolute change in total CVD risk (Framingham) — Mean absolute change, orforglipron doses (range)
- −0.6% to −1.00%
- Predicted ASCVD, HF and total CVD risks (PREVENT) · week 72 · Orforglipron vs Placebo
- P < 0.0001
Predicted ASCVD, HF and total CVD risks (PREVENT) · week 72
- Orforglipron associated with reduced predicted ASCVD, HF and total CVD risks vs placebo
Original publication
Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN ‐1 Trial. Diabetes Obes Metab. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →